Log in to your Inderes Free account to see all free content on this page.
Devyser Diagnostics
128.5
SEK
-3.38 %
DVYSR
First North Stockholm
Medical Equipment & Services
Health Care
2 following
-3.38%
-1.53%
+19.53%
+29.28%
+63.49%
+91.79%
-
-
+44.38%
investors.devyser.com/en
Devyser Diagnostics develops, manufactures, and sells genetic tests to laboratories globally. The products are used for DNA tests in oncology, transplantation, and hereditary diseases to enable tailored cancer treatment, diagnosis of a large number of genetic diseases, and follow-up of transplant patients. The company is headquartered in Hägersten.
Revenue
169.3M
EBIT %
-34.79 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
DVYSR
Daily low / high price
126.5 / 135
SEK
Market cap
2.12B SEK
Turnover
1.84M SEK
Volume
14K
Latest videos
Financial calendar
Annual report
13.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Rutger Arnhult, via bolag | 24.5 % | 24.5 % |
Nordnet Pensionsförsäkringar | 10.6 % | 10.6 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Nomination Committee Appointed Ahead of the 2025 Annual General Meeting in Devyser Diagnostics AB
Redeye: Devyser Q3 - All eyes on Q4
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio